BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14693749)

  • 1. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women.
    Arslan AA; Zeleniuch-Jacquotte A; Lundin E; Micheli A; Lukanova A; Afanasyeva Y; Lenner P; Krogh V; Muti P; Rinaldi S; Kaaks R; Berrino F; Hallmans G; Toniolo P
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1531-5. PubMed ID: 14693749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.
    Dorgan JF; Longcope C; Stephenson HE; Falk RT; Miller R; Franz C; Kahle L; Campbell WS; Tangrea JA; Schatzkin A
    Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):533-9. PubMed ID: 8827358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein concentrations and subsequent ovarian cancer risk.
    McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Pollak M; Tao Y; Helzlsouer KJ
    Obstet Gynecol; 2007 Apr; 109(4):933-41. PubMed ID: 17400857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychotropic medication use and risk of epithelial ovarian cancer.
    Harlow BL; Cramer DW; Baron JA; Titus-Ernstoff L; Greenberg ER
    Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):697-702. PubMed ID: 9718222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
    Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
    Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer.
    Wu K; Helzlsouer KJ; Comstock GW; Hoffman SC; Nadeau MR; Selhub J
    Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):209-17. PubMed ID: 10090298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
    Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
    Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum levels of follicle stimulating hormone (FSH) and prognosis in invasive breast cancer.
    Eskelinen M; Nordén T; Lindgren A; Wide L; Adami HO; Holmberg L
    Eur J Surg Oncol; 2004 Jun; 30(5):495-500. PubMed ID: 15135476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthropometry and the risk of epithelial ovarian cancer.
    Greer JB; Modugno F; Ness RB; Allen GO
    Cancer; 2006 May; 106(10):2247-57. PubMed ID: 16596653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender of offspring and maternal risk of invasive epithelial ovarian cancer.
    Baik I; Lambe M; Liu Q; Cnattingius S; Mucci LA; Riman T; Ekbom A; Adami HO; Hsieh CC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2314-20. PubMed ID: 18006920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
    J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations.
    Chubak J; Tworoger SS; Yasui Y; Ulrich CM; Stanczyk FZ; McTiernan A
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1296-301. PubMed ID: 15298949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen replacement therapy and ovarian cancer.
    Folsom AR; Anderson JP; Ross JA
    Epidemiology; 2004 Jan; 15(1):100-4. PubMed ID: 14712153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis.
    Tung KH; Wilkens LR; Wu AH; McDuffie K; Nomura AM; Kolonel LN; Terada KY; Goodman MT
    Am J Epidemiol; 2005 Feb; 161(4):321-9. PubMed ID: 15692075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
    Oh JC; Wu W; Tortolero-Luna G; Broaddus R; Gershenson DM; Burke TW; Schmandt R; Lu KH
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):748-52. PubMed ID: 15159305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and risk of epithelial ovarian cancer.
    Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
    Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic inflammatory disease and risk of ovarian cancer.
    Parazzini F; La Vecchia C; Negri E; Moroni S; dal Pino D; Fedele L
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):667-9. PubMed ID: 8824371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.